BPGbio
13
1
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Role: lead
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
Role: lead
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Role: lead
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
Role: collaborator
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Role: lead
Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors
Role: lead
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Role: lead
Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Role: collaborator
Project Survival-Prospective Biomarker Discovery
Role: collaborator
An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)
Role: lead
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Role: lead
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Role: lead
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
Role: lead
All 13 trials loaded